AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04246606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IHC4 score
Description: The IHC4 score is a prognostic tool that incorporates immunohistochemical parameters of ER (H-score), PR (% of positive cells), HER2 (positive or negative status), and Ki67 (% of positive cells).~IHC4 score, combined with nodal status and tumor grade, age, and the type of endocrine therapy (tamoxifen or aromatase inhibitors) provides a clinical score IHC4+C.~IHC4+C provides a prognostic risk of distant recurrence at 10 years for patients who underwent endocrine therapy for 5 years. IHC4+C defined three distinct risk categories:~* \<10%: low risk~* \[10-20%\]: intermediate risk~* >20%: high risk
Study NCT01004588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink
Description: total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
Study NCT01004588 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
Study NCT00559520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Impact
Description: Patient receiving 3 drinks Impact a day during 5 days before surgery
Study NCT00559520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact
Description: Patient receiving 3 drinks Oral Impact a day during 5 days before surgery
Study NCT02722447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Description: Rivaroxaban 20 mg for 6 weeks
Study NCT02722447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 6 weeks
Study NCT00977132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic aicd
Description: Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks.
Study NCT00977132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks
Study NCT02487212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% Clobetasol propionate
Description: 0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
Study NCT02487212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum gel
Description: Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
Study NCT02487212 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional Erbium:Yag (2,940-nm) laser
Description: The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
Study NCT02487212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Erbium:Yag (2,940-nm) laser
Description: The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
Study NCT02704078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-TBNA
Description: EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
Study NCT02704078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-B-FNA
Description: EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
Study NCT02363725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchimax®
Study NCT02363725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Study NCT02363725 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional treatment
Study NCT02803307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: Single dose via intra-articular injection
Study NCT00819338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Efamax
Description: 5g daily as capsules for 3 months
Study NCT00819338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Efamax
Description: 5g daily as capsules for 3 months
Study NCT00657241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol CR